Bavarian Nordic Announces Interim Results for the First Three Months of 2026 Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox Vaccines Bavarian Nordic Receives Swissmedic Approval for Chikungunya Vaccine Bavarian Nordic Submits Data to EMA to Extend Mpox and Smallpox Vaccine Approval to Children Aged 2-11 Years Bavarian Nordic Publishes Annual Report 2025 Bavarian Nordic and Serum Institute of India Expand Strategic Partnership with Chikungunya Vaccine Manufacturing Agreement Paul Chaplin Steps Down as CEO of Bavarian Nordic Bavarian Nordic Receives USD 22.5 Million Contract for its Mpox and Smallpox Vaccine from the Government of Canada Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026 Bavarian Nordic Signs Distribution Agreement with Eurofarma to Expand Access to Chikungunya Vaccine in Brazil Heidi Hunter Appointed New Vice Chair of the Board of Directors of Bavarian Nordic Bavarian Nordic to Launch Share Buy-back Program of up to DKK 500 Million Bavarian Nordic to Host a Shareholder Information Meeting on December 11, 2025 in Copenhagen Biotech unter Druck: Zahlen top, Aktie flop: Bavarian Nordic rutscht ins Minus! Bavarian Nordic Announces Interim Results for the First Nine Months of 2025